CrossRef Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events Daqiu Chen, Zixun Wang, Zhanxiong Xie, Yixing Chen, Shunxiang Luo, Shanghua Xu Frontiers in Pharmacology.2026;[Epub] CrossRef Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study Ying Wang, Hongning Li, Zhongyuan Zhang, Xiaocen Kong, Huiqin Li, Weichun Qian, Jianhua Ma Frontiers in Endocrinology.2026;[Epub] CrossRef Inflammation-autonomic cross talk contributes to left ventricular diastolic dysfunction in type 2 diabetes: a rationale for neuromodulation Nuwani Wijesooriya, Senali Silva, Dulani Kottahachchi, Nadisha Badanasinghe, Dinu S
More than half of those users say theyre having trouble covering the cost of treatment, according to a Kaiser Family Foundation poll
A typical 16-week titration moves from 0.25 mg to 0.5 mg, then to 1.0 mg, and finally to 2.4 mg as your maintenance dose
Observation of subpopulation responses indicates this is not the case (Yip et al., 2016) and repeatedly emphasizes the highly individualized character of many chronic illnesses
You might even have a diagnosis like Hashimotos or Rheumatoid Arthritis